Dr. Reddy's Launches Nivolumab Biosimilar NIVORZ in India for Cancer Treatment
Dr. Reddy's Laboratories has launched NIVORZ, a biosimilar of Bristol Myers Squibb's Opdivo (nivolumab), in India. Developed and manufactured in-house at its Hyderabad biologics facility, NIVORZ is approved by the Drugs Controller General of India for 12 cancer indications, including solid tumors and blood cancers. The intravenous therapy aims to improve patient access to affordable immuno-oncology treatments in a market estimated at Rs 3,900 crore in 2025. Clinical trials demonstrated comparable efficacy and safety to the reference drug.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (70/100). Lens Score 41/100.
Outlets measured: economictimes, news18, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (62–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 15 Sept, 12:11 pm. Other outlets followed.